Not disclosed data

TELR (Woburn, Mass.) announced results of a Phase I/II trial of a drug treatment for the loss of acuity common with aging, which is currently corrected with reading glasses. A single treatment with the agent, in an eye drop, resulted in statistically significant improvement in 24 patients in the ability to focus on print.

The identity of the agents being tested has not been disclosed, as patents haven't yet issued. ...